View the slide viewer

Have questions about this assay kit?

Human ERRg Reporter Assay Kit

1 x-96 well format assays$910 USD
3 x-32 assays in-96 well format$980 USD
1 x-384 well format assays$2300 USD
1 x-96 well format assays
3 x-32 assays in-96 well format
1 x-384 well format assays

Product Description and Product Data

This is an all-inclusive cell-based luciferase reporter assay kit targeting the Human Estrogen-Related Receptor Gamma (ERRg). INDIGO’s ERR Gamma reporter assay utilizes proprietary mammalian cells that have been engineered to provide constitutive expression of the ERR Gamma. In addition to ERR Gamma Reporter Cells, this kit provides two optimized media for use during cell culture and in diluting the user’s test samples, a reference agonist, Luciferase Detection Reagent, and a cell culture-ready assay plate. The principal application of this assay is in the screening of test samples to quantify any functional activities, either agonist or inverse-agonist that they may exert against human ERR Gamma. This kit provides researchers with clear, reproducible results, exceptional cell viability post-thaw, and consistent results lot to lot. Kits must be stored at -80C. Do not store in liquid nitrogen. Note: reporter cells cannot be refrozen or maintained in extended culture.


  • Clear, Reproducible Results

  • All-Inclusive Assay Systems
  • Exceptional Cell Viability Post-Thaw
  • Consistent Results Lot to Lot

Product Specifications

Target TypeNuclear Hormone Receptor
Receptor FormHybrid
Assay ModeInverse Agonist
Kit Components
  • ERRg Reporter Cells
  • Cell Recovery Medium (CRM)
  • Compound Screening Medium (CSM)
  • 4-Hydroxy Tamoxifen, (ref. inverse-agonist; in DMSO)
  • Detection Substrate
  • Detection Buffer
  • White, sterile, cell-culture ready assay plate
Shelf Life6 months
Orthologs AvailableNo
Shipping RequirementsDry Ice
Storage temperature-80C


ERRγ Assays were performed using A.) the reference agonists GSK4716 and DY131 (Tocris), and B.) the inverse-agonists 4-Hydroxy Tamoxifen (provided), DY40 and DY181. INDIGO’s Live Cell Multiplex assay confirmed that none of the treatment concentrations induced cytotoxicity (data not shown). Averaged relative light units (RLU) and their corresponding values of standard deviation and percent coefficient of variation were determined for each treatment concentration (n = 3). Values of fold-activation (F/A) and fold-reduction (F/R) in ERRγ activities were calculated by normalizing respective RLU values from test compound-treated reporter cells to the RLU value of untreated reporter cells. Z’ values were calculated as described by Zhang, et al. (1999). Non-linear regression and respective EC50 and IC50 determination were performed using GraphPad Prism software.

Target Background

INDIGO’s Estrogen-related Receptor Gamma cell-based assay systems utilize proprietary mammalian cells engineered to provide high-level expression of a hybrid form of Human ERRγ (also known as NR3B3).

Reporter Cells also incorporate a responsive luciferase reporter gene. Quantifying expressed luciferase activity at the assay endpoint provides a sensitive surrogate measure of changes in ERRγ activity in treated cells. As is true in vivo, these reporter cells express ERRγ in a constitutive state of high-level activity in the putative absence of bound ligand. Interestingly, the ligand binding domain of ERRγ may be occupied by a ligand that produces further elevation of the receptor’s constitutive activity (an agonist response). Alternatively, ERRγ may have ligand-binding interactions that results in the loss of constitutive active (an inverse-agonist response).

Therefore, the principle application of this assay system is in the screening of test samples to quantify the agonist or inverse-agonist activities that they may exert against human ERRγ.

Also available as a service

Estrogen-related Receptor Gamma (ERRg, NR3B3)

Have questions about this assay kit?